Progression in attenuating myocardial reperfusion injury: An overview

International Journal of Cardiology

Volumn 170, Issue 3, 2014, Pages 261-269

  Bernink, F J P ^a   Timmers, L ^b   Beek, A M ^a   Diamant, M ^a   Roos, S T ^a   Van Rossum, A C ^a   Appelman, Y ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Myocardial infarction; Myocardial reperfusion injury; Percutaneous coronary intervention

Indexed keywords

ADENOSINE; ATRIAL NATRIURETIC FACTOR; CYCLOSPORIN; EXENDIN 4; GLUCOSE; INSULIN; PLACEBO; POTASSIUM CHLORIDE;

ACUTE HEART INFARCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC PRECONDITIONING; NONHUMAN; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION;

HUMANS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; THROMBOLYTIC THERAPY;

EID: 84891024627     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.11.007     Document Type: Review

References (94)

1. E.C. Keeley, J.A. Boura, and C.L. Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 9351 2003 13 20
2. R.J. Burns, R.J. Gibbons, and Q. Yi et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis J Am Coll Cardiol 39 1 2002 30 36
3. R.J. Gibbons, U.S. Valeti, P.A. Araoz, and A.S. Jaffe The quantification of infarct size J Am Coll Cardiol 44 8 2004 1533 1542
4. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 11 2007 1121 1135
5. H.M. Piper, D. Garcia-Dorado, and M. Ovize A fresh look at reperfusion injury Cardiovasc Res 38 2 1998 291 300
6. S. Sanada, I. Komuro, and M. Kitakaze Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures Am J Physiol Heart Circ Physiol 301 5 2011 H1723 H1741
7. M.F. Oliver Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes Am J Med 112 4 2002 305 311
8. L. Timmers, G. Pasterkamp, V.C. de Hoog, F. Arslan, Y. Appelman, and D.P. de Kleijn The innate immune response in reperfused myocardium Cardiovasc Res 94 2 2012 276 283
9. B. Ibanez, V. Fuster, J. Jimenez-Borreguero, and J.J. Badimon Lethal myocardial reperfusion injury: a necessary evil? Int J Cardiol 151 1 2011 3 11
10. D.J. Hausenloy, M.R. Duchen, and D.M. Yellon Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury Cardiovasc Res 60 3 2003 617 625
11. C.E. Murry, R.B. Jennings, and K.A. Reimer Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Circulation 74 5 1986 1124 1136
12. S.R. Walsh, T.Y. Tang, P. Kullar, D.P. Jenkins, D.P. Dutka, and M.E. Gaunt Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials Eur J Cardiothorac Surg 34 5 2008 985 994
13. Z.Q. Zhao, J.S. Corvera, and M.E. Halkos et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning Am J Physiol Heart Circ Physiol 285 2 2003 H579 H588
14. P. Staat, G. Rioufol, and C. Piot et al. Postconditioning the human heart Circulation 112 14 2005 2143 2148
15. X. Ma, X. Zhang, C. Li, and M. Luo Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction J Interv Cardiol 19 5 2006 367 375
16. X.C. Yang, Y. Liu, and L.F. Wang et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention J Invasive Cardiol 19 10 2007 424 430
17. H. Thibault, C. Piot, and P. Staat et al. Long-term benefit of postconditioning Circulation 117 8 2008 1037 1044
18. J. Lonborg, H. Kelbaek, and N. Vejlstrup et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance Circ Cardiovasc Interv 3 1 2010 34 41
19. P. Sorensson, N. Saleh, and F. Bouvier et al. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction Heart 96 21 2010 1710 1715
20. G. Tarantini, E. Favaretto, and M. Napodano et al. Design and methodologies of the postconditioning during coronary angioplasty in acute myocardial infarction (POST-AMI) trial Cardiology 116 2 2010 110 116
21. K. Przyklenk, C.E. Darling, E.W. Dickson, and P. Whittaker Cardioprotection 'outside the box' - the evolving paradigm of remote preconditioning Basic Res Cardiol 98 3 2003 149 157
22. B.C. Gho, R.G. Schoemaker, M.A. van den Doel, D.J. Duncker, and P.D. Verdouw Myocardial protection by brief ischemia in noncardiac tissue Circulation 94 9 1996 2193 2200
23. S.Y. Lim, D.M. Yellon, and D.J. Hausenloy The neural and humoral pathways in remote limb ischemic preconditioning Basic Res Cardiol 105 5 2010 651 655
24. M. Thielmann, E. Kottenberg, and P. Kleinbongard et al. Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial Lancet 382 9892 2013 597 604
25. H.E. Botker, R. Kharbanda, and M.R. Schmidt et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial Lancet 375 9716 2010 727 734
26. J.R. Spears, P. Prcevski, A. Jiang, G.J. Brereton, and H.R. Vander Intracoronary aqueous oxygen perfusion, performed 24 h after the onset of postinfarction reperfusion, experimentally reduces infarct size and improves left ventricular function Int J Cardiol 113 3 2006 371 375
27. S.R. Dixon, A.L. Bartorelli, and P.A. Marcovitz et al. Initial experience with hyperoxemic reperfusion after primary angioplasty for acute myocardial infarction: results of a pilot study utilizing intracoronary aqueous oxygen therapy J Am Coll Cardiol 39 3 2002 387 392
28. W.W. O'Neill, J.L. Martin, and S.R. Dixon et al. Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention J Am Coll Cardiol 50 5 2007 397 405
29. G.W. Stone, J.L. Martin, and M.J. de Boer et al. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction Circ Cardiovasc Interv 2 5 2009 366 375
30. X. Wang, M. Wei, and P. Kuukasjarvi et al. Novel pharmacological preconditioning with diazoxide attenuates myocardial stunning in coronary artery bypass grafting Eur J Cardiothorac Surg 24 6 2003 967 973
31. S. Post, M.C. Post, and B.J. van den Branden et al. Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial Catheter Cardiovasc Interv 80 5 2012 756 765
32. P.W. Armstrong, C.B. Granger, and P.X. Adams et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 1 2007 43 51
33. F.W. Bar, D. Tzivoni, and M.T. Dirksen et al. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: the randomized multicentre CASTEMI study Eur Heart J 27 21 2006 2516 2523
34. W. Chan, A.J. Taylor, and A.H. Ellims et al. Effect of iron chelation on myocardial infarct size and oxidative stress in ST-elevation-myocardial infarction Circ Cardiovasc Interv 5 2 2012 270 278
35. J.T. Flaherty, B. Pitt, and J.W. Gruber et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction Circulation 89 5 1994 1982 1991
36. K. Iwakura, H. Ito, and A. Okamura et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis Circ J 73 5 2009 925 931
37. I.K. Jang, N.J. Weissman, and M.H. Picard et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE) Am Heart J 155 1 2008 113 118
38. M. Kitakaze, M. Asakura, and J. Kim et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials Lancet 370 9597 2007 1483 1493
39. P. Theroux, B.R. Chaitman, and N. Danchin et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators Circulation 102 25 2000 3032 3038
40. K. Tsujita, H. Shimomura, and H. Kawano et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction Am J Cardiol 94 4 2004 481 484
41. D. Tzivoni, J. Balkin, F.W. Bar, M. Hibberd, J.H. Reiber, and G. Cowing Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention Am J Cardiol 103 1 2009 1 4
42. U. Zeymer, H. Suryapranata, and J.P. Monassier et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial J Am Coll Cardiol 38 6 2001 1644 1650
43. S.S. Najjar, S.V. Rao, and C. Melloni et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial JAMA 305 18 2011 1863 1872
44. D. Gao, N. Ning, and X. Niu et al. Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials Am Heart J 164 5 2012 715 727
45. T. Minamino, K. Toba, and S. Higo et al. Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): a randomized controlled clinical trial Cardiovasc Drugs Ther 26 5 2012 409 416
46. S. Kasama, M. Furuya, T. Toyama, S. Ichikawa, and M. Kurabayashi Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction Eur Heart J 29 12 2008 1485 1494
47. A. Kudoh, H. Katagai, and T. Takazawa Atrial natriuretic peptide increases glucose uptake during hypoxia in cardiomyocytes J Cardiovasc Pharmacol 40 4 2002 601 610
48. M.V. Cohen, and J.M. Downey Adenosine: trigger and mediator of cardioprotection Basic Res Cardiol 103 3 2008 203 215
49. M. Marzilli, E. Orsini, P. Marraccini, and R. Testa Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction Circulation 101 18 2000 2154 2159
50. W. Desmet, J. Bogaert, and C. Dubois et al. High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction Eur Heart J 32 7 2011 867 877
51. A.M. Ross, R.J. Gibbons, G.W. Stone, R.A. Kloner, and R.W. Alexander A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) J Am Coll Cardiol 45 11 2005 1775 1780
52. K.W. Mahaffey, J.A. Puma, and N.A. Barbagelata et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial J Am Coll Cardiol 34 6 1999 1711 1720
53. R.A. Kloner, M.B. Forman, R.J. Gibbons, A.M. Ross, R.W. Alexander, and G.W. Stone Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial Eur Heart J 27 20 2006 2400 2405
54. E.P. Navarese, A. Buffon, and F. Andreotti et al. Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials Atherosclerosis 222 1 2012 1 7
55. M.R. Duchen, O. McGuinness, L.A. Brown, and M. Crompton On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury Cardiovasc Res 27 10 1993 1790 1794
56. W.Y. Lim, C.M. Messow, and C. Berry Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta-analysis Br J Pharmacol 165 7 2012 2034 2043
57. C. Piot, P. Croisille, and P. Staat et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction N Engl J Med 359 5 2008 473 481
58. N. Mewton, P. Croisille, and G. Gahide et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction J Am Coll Cardiol 55 12 2010 1200 1205
59. Rationale and design of the 'MITOCARE' study: a phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of TRO40303 for the reduction of reperfusion injury in patients undergoing percutaneous coronary intervention for acute myocardial infarction Cardiology 123 4 2012 201 207
60. D. Sodi-Pallares, M.R. Testelli, and B.L. Fishleder et al. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report Am J Cardiol 9 1962 166 181
61. M.F. Oliver, and L.H. Opie Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias Lancet 343 8890 1994 155 158
62. M.A. Mamas, L. Neyses, and F. Fath-Ordoubadi A meta-analysis of glucose-insulin-potassium therapy for treatment of acute myocardial infarction Exp Clin Cardiol 15 2 2010 e20 e24
63. C.E. Rackley, R.O. Russell Jr., W.J. Rogers, J.A. Mantle, H.G. McDaniel, and S.E. Papapietro Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction Am Heart J 102 6 Pt 1 1981 1038 1049
64. F. Fath-Ordoubadi, and K.J. Beatt Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials Circulation 96 4 1997 1152 1156
65. Y.T. Zhao, C.L. Weng, and M.L. Chen et al. Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials Heart 96 20 2010 1622 1626
66. L. Ceremuzynski, A. Budaj, and A. Czepiel et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial Cardiovasc Drugs Ther 13 3 1999 191 200
67. R. Diaz, E.A. Paolasso, and L.S. Piegas et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) collaborative group Circulation 98 21 1998 2227 2234
68. S.R. Mehta, S. Yusuf, and R. Diaz et al. Effect of glucose-insulin- potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial JAMA 293 4 2005 437 446
69. J.R. Timmer, T. Svilaas, and J.P. Ottervanger et al. Glucose-insulin- potassium infusion in patients with acute myocardial infarction without signs of heart failure: the Glucose-Insulin-Potassium Study (GIPS) - II J Am Coll Cardiol 47 8 2006 1730 1731
70. S. Rasoul, J.P. Ottervanger, and J.R. Timmer et al. One year outcomes after glucose-insulin-potassium in ST elevation myocardial infarction. The Glucose-Insulin-Potassium Study II Int J Cardiol 122 1 2007 52 55
71. I.C. van der Horst, F. Zijlstra, and A.W. van 't Hof et al. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial J Am Coll Cardiol 42 5 2003 784 791
72. K. Malmberg, L. Ryden, and S. Efendic et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year J Am Coll Cardiol 26 1 1995 57 65
73. K. Malmberg, L. Ryden, and H. Wedel et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity Eur Heart J 26 7 2005 650 661
74. H.P. Selker, J.R. Beshansky, and P.R. Sheehan et al. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial JAMA 307 18 2012 1925 1933
75. I.C. van der Horst, J.R. Timmer, and J.P. Ottervanger et al. Glucose-insulin-potassium and reperfusion in acute myocardial infarction: rationale and design of the Glucose-Insulin-Potassium Study - 2 (GIPS-2) Am Heart J 149 4 2005 585 591
76. D.J. Drucker The biology of incretin hormones Cell Metab 3 3 2006 153 165
77. D. Mundil, A. Cameron-Vendrig, and M. Husain GLP-1 receptor agonists: a clinical perspective on cardiovascular effects Diab Vasc Dis Res 9 2 2012 95 108
78. Y. Wei, and S. Mojsov Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences FEBS Lett 358 3 1995 219 224
79. T. Zhao, P. Parikh, and S. Bhashyam et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts J Pharmacol Exp Ther 317 3 2006 1106 1113
80. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 1 2005 146 151
81. L.A. Nikolaidis, S. Mankad, and G.G. Sokos et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion Circulation 109 8 2004 962 965
82. P.A. Read, S.P. Hoole, and P.A. White et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans Circ Cardiovasc Interv 4 3 2011 266 272
83. R.E. van Genugten, D.H. van Raalte, and M. Diamant Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide Diabetes Res Clin Pract 86 Suppl. 1 2009 S26 S34
84. L. Timmers, J.P. Henriques, and D.P. de Kleijn et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury J Am Coll Cardiol 53 6 2009 501 510
85. J. Kristensen, U.M. Mortensen, M. Schmidt, P.H. Nielsen, T.T. Nielsen, and M. Maeng Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model BMC Cardiovasc Disord 9 2009 31
86. J. Lonborg, N. Vejlstrup, and H. Kelbaek et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur Heart J 33 12 2012 1491 1499
87. J. Lonborg, H. Kelbaek, and N. Vejlstrup et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia Circ Cardiovasc Interv 5 2 2012 288 295
88. J.S. Woo, W. Kim, and S.J. Ha et al. Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study Arterioscler Thromb Vasc Biol 33 9 2013 2252 2260
89. F.J. Bernink, L. Timmers, and M. Diamant et al. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: the EXAMI study Int J Cardiol 167 1 2013 289 290
90. M. Scholte, L. Timmers, and F.J. Bernink et al. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial Trials 12 2011 240
91. P. Croisille, H.W. Kim, and R.J. Kim Controversies in cardiovascular MR imaging: T2-weighted imaging should not be used to delineate the area at risk in ischemic myocardial injury Radiology 265 1 2012 12 22
92. A.E. Arai, S. Leung, and P. Kellman Controversies in cardiovascular MR imaging: reasons why imaging myocardial T2 has clinical and pathophysiologic value in acute myocardial infarction Radiology 265 1 2012 23 32
93. R. Bolli, L. Becker, G. Gross, R. Mentzer Jr., D. Balshaw, and D.A. Lathrop Myocardial protection at a crossroads: the need for translation into clinical therapy Circ Res 95 2 2004 125 134
94. J. Slikkerveer, S.A. Kleijn, and Y. Appelman et al. Ultrasound enhanced prehospital thrombolysis using microbubbles infusion in patients with acute ST elevation myocardial infarction: pilot of the Sonolysis study Ultrasound Med Biol 38 2 2012 247 252